"A US federal jury has determined that Apple must pay medical technology company Masimo $634 million (roughly Rs. 5,620 crore) for infringing a patent related to blood oxygen-sensing technology used in the Apple Watch, according to a Reuters report. The Cupertino company is expected to appeal the decision. Masimo said in a statement that it viewed the verdict as a positive outcome, noting that the ruling supports its long-running effort to safeguard its innovations and intellectual property."
"According to Reuters, an Apple spokesperson said that although Masimo has taken the company to court many times over the past six years, bringing more than two dozen patent claims, most of those claims were found to be invalid. The company also noted that the single patent involved in this ruling expired in 2022 and is based on older patient-monitoring technology. The dispute previously triggered a ban on US sales of Apple Watch models featuring blood oxygen monitoring in December 2023."
A US federal jury ordered Apple to pay Masimo $634 million for infringing a blood oxygen-sensing patent used in the Apple Watch. Apple is expected to appeal the decision. Masimo described the verdict as a positive outcome that supports its long-running effort to safeguard innovations and intellectual property, and said protecting its technology is essential to developing products that benefit patients. Apple noted that Masimo filed many claims over six years and that most were found invalid, and that the single patent at issue expired in 2022 and was based on older patient-monitoring technology. The dispute previously led to a US sales ban in December 2023, and Apple sold affected watches with the blood oxygen feature disabled to comply.
Read at Gadgets 360
Unable to calculate read time
Collection
[
|
...
]